For some individuals living with depression, initial medication or psychotherapy may not result in sufficient improvement. A portion of patients experience what is commonly referred to as treatment-resistant depression (TRD), in which symptoms persist despite multiple treatment attempts. In these situations, additional evaluation and alternative approaches may be considered.
At Mental Health Management Group, care is led by a licensed psychiatric provider and may include office-based neuromodulation services such as Transcranial Magnetic Stimulation (TMS), ExoMind neuromodulation, or physician-supervised ketamine-based treatments when clinically appropriate. Treatment planning is individualized and based on comprehensive psychiatric evaluation.
What Is Treatment-Resistant Depression?
Treatment-resistant depression is generally described as major depressive disorder that does not remit after at least two adequate antidepressant trials. Clinical literature has emphasized the need for alternative or adjunctive strategies when standard medication regimens do not produce sufficient symptom reduction, including findings from a multisite randomized controlled trial examining TMS in treatment-resistant depression (O’Reardon et al., 2007).
When medication alone does not lead to improvement, this may indicate that additional treatment modalities should be evaluated rather than discontinued care.
A Network-Based Understanding of Depression
Recent psychiatric research has explored depression as a condition involving interconnected brain networks, including the salience network, default mode network, and central executive network. These networks influence mood, motivation, emotional regulation, and cognitive control.
Neuromodulation approaches and ketamine-based treatments have been studied for their potential to influence these neural circuits. Research continues to examine how combination approaches may affect network connectivity in individuals with treatment-resistant depression.
How TMS, ExoMind, and Ketamine-Based Treatments May Be Used
Transcranial Magnetic Stimulation (TMS)
TMS is a non-invasive neuromodulation service that uses magnetic pulses to stimulate specific brain regions involved in mood regulation. TMS is cleared by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder in certain populations and is delivered in an outpatient setting.
ExoMind Neuromodulation
ExoMind is a magnetic neuromodulation approach designed to engage interconnected brain networks. It is FDA-cleared for depression care. Treatment protocols are determined through psychiatric evaluation and individualized planning.
Ketamine-Based Therapy
Ketamine-based treatments are administered under medical supervision and have been studied for rapid-acting antidepressant effects in certain populations with treatment-resistant depression. Delivery methods vary and are selected based on clinical appropriateness and safety considerations.
When considered together, these approaches may be integrated into a broader treatment plan. Decisions regarding sequencing or combination of therapies are made based on symptom profile, treatment history, and medical evaluation.
What Is Neuromodulation?
Neuromodulation refers to altering nerve activity through targeted stimulation of specific brain regions. In psychiatric care, this typically involves magnetic stimulation aimed at influencing communication between neural networks involved in mood and cognition.
The goal of neuromodulation is to support regulation of brain circuits associated with depressive symptoms. Individual responses vary, and ongoing monitoring is part of care.
Research on Combination Approaches
Clinical studies have examined TMS and ketamine separately for treatment-resistant depression. Some emerging research has explored the potential effects of combining these modalities, with findings suggesting possible additive or complementary effects in certain populations. Outcomes vary, and further research is ongoing.
When multiple approaches are considered, careful screening and psychiatric oversight are essential to ensure safety and appropriateness.
Considerations for Patients With Treatment-Resistant Depression
Individuals who have not experienced sufficient improvement with antidepressants may benefit from a comprehensive re-evaluation of diagnosis, medical history, and prior treatment response. This assessment may include discussion of:
- Neuromodulation services such as TMS or ExoMind
- Ketamine-based treatments when clinically appropriate
- Psychotherapy and behavioral strategies
- Lifestyle and sleep interventions
- Medication adjustments
Treatment plans are individualized rather than standardized.
The Future of Depression Care
Research continues to explore multimodal and network-based approaches to depression. As understanding of brain circuitry advances, psychiatric care increasingly focuses on personalized treatment selection guided by clinical assessment and evidence.
Next Steps
If you have not experienced sufficient improvement with antidepressants or therapy, a psychiatric consultation can help determine whether additional options may be appropriate. Appointments can be requested by calling (813) 657-7022.
Informational Disclaimer
The information provided in this article is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Clinical services are provided following an individualized evaluation by a licensed healthcare professional.
